D.H.F. Gommans, J. Nas, S.-J. Pinto-Sietsma, Y. Koop, R.E. Konst, F.B. Mensink, G.W.A. Aarts, L.S.F. Konijnenberg, K. Cortenbach, D.V.M. Verhaert, J. Thannhauser, J.H.Q. Mol, M.J.P. Rooijakkers, J.L. Vos, A. van Rumund, P. Vart, R.-J. Hassing, J.-H. Cornel, C.P.C. de Jager, M.M. van den Heuvel, H.G. van der Hoeven, A. Verbon, M. Yigal, N. van Royen, Roland R.J. van Kimmenade,

Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.

American Heart Journal (2020), https://doi.org/10.1016/j.ahj.2020.05.010

VALSARTAN ARB COVID PLACEBO COVID-19 PRAETORIAN PRAETORIAN-COVID TRIAL STUDY PRAETORIAN PRAETORIAN PRAETORIAN PRAETORIAN PRAETORIAN PRAETORIAN PRAETORIAN COVID COVID COVID COVID COVID COVID COVID PRAETORIAN-COVID PRAETORIAN-COVID PRAETORIAN-COVID PRAETORIAN-COVID VALSARTAN COVID VALSARTAN COVID VALSARTAN COVID VALSARTAN COVID VALSARTAN COVID